Industry Research Reports
Home > Reports > Pharma & Healthcare > Mucin 1- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
Mucin 1- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
Industry: Pharma & Healthcare
Published Date: 2026-05-30
Pages: 193 Pages
Report ld: 6719098
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Mucin 1 Market Size(US$)
CAGR 2026-2032
10.8%
Market Size,2032
USD 620
Million
Market Snapshot
Market Size in 2026 (Value)
US$ 335 million
Market Forecast in 2032(Value)
US$ 620 million
CAGR
10.8%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032
Source: Secondary research, interviews with experts, and QYResearch analysis
The global market for Mucin 1 was estimated to be worth US$ 300 million in 2025 and is projected to reach US$ 620 million, growing at a CAGR of 10.8% from 2026 to 2032.
The potential shifts in the 2025 U.S. tariff framework pose substantial volatility risks to global markets. This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Mucin 1 cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
Mucin 1 is a membrane-bound, highly glycosylated glycoprotein expressed by epithelial cells. Under physiological conditions, it is mainly located on the apical surface of mucosal epithelial cells and contributes to mucus barrier formation, cellular protection, cell adhesion, and signal transduction. In an industrial context, Mucin 1 products generally do not refer to the native protein in the human body alone, but to a product family built around this target, including recombinant proteins, synthetic peptides, monoclonal antibodies, polyclonal antibodies, antibody pairs, immunoassay kits, diagnostic reagents, and targeted therapeutic candidates. Commercial forms include lyophilized powder, liquid reagents in buffer, pre-coated microplate kits, labeled antibodies, cell therapy preparations, and injectable investigational drugs. Key technical requirements include sequence accuracy, preservation of glycosylation or epitope conformation, antibody specificity, lot-to-lot consistency, endotoxin control, sterility control, and target-binding validation. Its mechanism of action is mainly based on antigen epitope recognition, abnormal glycoform recognition, immune response induction, cell killing, or targeted delivery, supporting oncology research, pathology testing, serum biomarker detection, drug screening, antibody drug development, cell therapy, and cancer vaccine research.
The main opportunities in the Mucin 1-related market are driven by both precision oncology and life science tool products. Abnormal glycosylation and altered localization in tumor tissues give this target broad research relevance across multiple cancer types, especially in antibody screening, pathology testing, tumor biomarker development, antibody-drug conjugates, cell therapy, and cancer vaccine development. As oncology drug development moves from conventional cytotoxic approaches toward targeted delivery, immune modulation, and combination therapy, products focused on specific epitopes, abnormal glycoforms, and intracellular signaling structures are likely to attract higher research investment and support growing demand for high-quality antibodies, recombinant proteins, cell lines, and clinical-grade materials.
The key challenges are target selectivity, clinical translation, and commercialization uncertainty. Mucin 1 is also expressed in normal epithelial tissues, so therapeutic products may face a narrow safety window, inconsistent efficacy, or difficulty in patient selection if they cannot clearly distinguish normal expression from tumor-associated abnormal expression. Previous clinical setbacks in cancer vaccines and certain targeted candidates show that development based only on total protein expression is not sufficient. Future competition will shift toward more precise epitope recognition, stronger delivery platforms, more reliable companion testing, and clearer patient stratification.
Downstream demand will gradually move from basic research purchasing toward higher validation standards, clinical translation, and scalable testing. Universities, hospitals, and pharmaceutical companies will continue to purchase antibodies, recombinant proteins, assay kits, and cell models for mechanistic studies, while incremental demand will increasingly come from tumor pathology, serum biomarkers, drug screening, antibody drug development, and cell therapy. Diagnostic users will place more emphasis on stability, reproducibility, and regulatory compliance, while drug developers will focus on epitope specificity, in vivo safety, and compatibility with patient stratification testing. Suppliers with quality systems, validation data, and clinical collaboration resources will be better positioned to win long-term orders.
This report provides a comprehensive view of the global market for Mucin 1, covering total sales volume, sales revenue, pricing, the market share and ranking of key companies, along with analyses by region & country, by Type, and by Application.
The Mucin 1 market size, estimations, and forecasts are presented in terms of sales volume (K Dose) and revenue ($ millions), with 2025 as the base year and historical and forecast data from 2021 to 2032. The report combines quantitative and qualitative analysis to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current marketplace, and make informed business decisions regarding Mucin 1.
MARKET SEGMENTATION
By Company
- Thermo Fisher Scientific
- Roche Diagnostics
- Abbott
- Siemens Healthineers
- Beckman Coulter
- DiaSorin
- Merck KGaA
- BD
- Bio-Rad Laboratories
- Agilent Technologies
- Leica Biosystems
- Bio-Techne
- Abcam
- Cell Signaling Technology
- BioLegend
- Miltenyi Biotec
- Fujirebio
- Medix Biochemica
- Sino Biological
- ACROBiosystems
- Proteintech
- ABclonal
- OriGene
- Santa Cruz Biotechnology
- GeneTex
- Atlas Antibodies
- Abnova
- Boster Bio
- Elabscience
- CUSABIO
- Cloud-Clone
- FineTest
- RayBiotech
- Creative Diagnostics
- Creative BioMart
- Boditech Med
- Daiichi Sankyo
- ImmunityBio
- GeoVax
- Minerva Biotechnologies
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Mucin 1 Protein
- Mucin 1 Peptide
- Anti-Mucin 1 Antibody
Segment by Application
- Prostate Cancer
- Breast Cancer
- Colon Cancer
- Ovarian Cancer
- Others
Segment by Category
- Human Mucin 1
- Mouse Mucin 1
- Rat Mucin 1
Segment by Division
- Lyophilized Powder
- Liquid Reagent
CHAPTER OUTLINE
Chapter 1: Introduces the scope of the report and the global market size (value, volume, and price). It also summarizes market dynamics and Recent Developments; identifies key drivers and restraints; outlines challenges and risks for manufacturers; reviews relevant industry policies and U.S. tariff implications.
Chapter 2: Provides a detailed analysis of the Mucin 1 manufacturers' competitive landscape—including pricing, sales and revenue shares, Recent Developments plans, and mergers and acquisitions (M&A).
Chapter 3: Analyzes market segmentation by Type, presenting the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 4: Analyzes market segmentation by Application, presenting the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 5: Presents Mucin 1 sales and revenue at the regional level. It offers a quantitative assessment of market size and growth potential by region and summarizes market development, future prospects, addressable space, and country-level market size worldwide.
Chapter 6: Presents Mucin 1 sales and revenue at the country level. It provides segmented data by Type and by Application for each country/region.
Chapter 7: Profiles key players, detailing the main companies' product sales, revenue, pricing, gross margin, product portfolios, Recent Developments, etc.
Chapter 8: Analyzes the industry value chain, including upstream suppliers and downstream applications/customers.
Chapter 9: Conclusion.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Market Overview
1.1 Mucin 1 Product Introduction
1.2 Global Mucin 1 Market Size Forecast
1.2.1 Global Mucin 1 Sales Value (2021–2032)
1.2.2 Global Mucin 1 Sales Volume (2021–2032)
1.2.3 Global Mucin 1 Sales Price (2021–2032)
1.3 Mucin 1 Market Trends & Drivers
1.3.1 Mucin 1 Industry Trends
1.3.2 Mucin 1 Market Drivers & Opportunities
1.3.3 Mucin 1 Market Challenges
1.3.4 Mucin 1 Market Restraints
1.3.5 Impact of U.S. Tariffs
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Mucin 1 Players Revenue Ranking (2025)
2.2 Global Mucin 1 Revenue by Company (2021–2026)
2.3 Global Mucin 1 Sales Volume Ranking of Players (2025)
2.4 Global Mucin 1 Sales Volume by Company (2021–2026)
2.5 Global Mucin 1 Average Price by Company (2021–2026)
2.6 Key Manufacturers Mucin 1 Manufacturing Base and Headquarters
2.7 Key Manufacturers Mucin 1 Product Offerings
2.8 Key Manufacturers Start of Mass Production of Mucin 1
2.9 Mucin 1 Market Competitive Analysis
2.9.1 Mucin 1 Market Concentration Rate (2021–2026)
2.9.2 Global 5 and 10 Largest Manufacturers by Mucin 1 Revenue in 2025
2.9.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Mucin 1 revenue, 2025
2.10 Mergers & Acquisitions and Expansion
3 Segmentation Mucin 1 Market Classification
3.1 Introduction by Type
3.1.1 Mucin 1 Protein
3.1.2 Mucin 1 Peptide
3.1.3 Anti-Mucin 1 Antibody
3.1.4 Global Mucin 1 Sales Value by Type
3.1.4.1 Global Mucin 1 Sales Value by Type (2021 vs 2025 vs 2032)
3.1.4.2 Global Mucin 1 Sales Value, by Type (2021–2032)
3.1.4.3 Global Mucin 1 Sales Value, by Type (%), 2021–2032
3.1.5 Global Mucin 1 Sales Volume by Type
3.1.5.1 Global Mucin 1 Sales Volume by Type (2021 vs 2025 vs 2032)
3.1.5.2 Global Mucin 1 Sales Volume, by Type (2021–2032)
3.1.5.3 Global Mucin 1 Sales Volume, by Type (%), 2021–2032
3.1.6 Global Mucin 1 Average Price by Type (2021–2032)
3.2 Introduction by Species
3.2.1 Human Mucin 1
3.2.2 Mouse Mucin 1
3.2.3 Rat Mucin 1
3.2.4 Global Mucin 1 Sales Value by Species
3.2.4.1 Global Mucin 1 Sales Value by Species (2021 vs 2025 vs 2032)
3.2.4.2 Global Mucin 1 Sales Value, by Species (2021–2032)
3.2.4.3 Global Mucin 1 Sales Value, by Species (%), 2021–2032
3.2.5 Global Mucin 1 Sales Volume by Species
3.2.5.1 Global Mucin 1 Sales Volume by Species (2021 vs 2025 vs 2032)
3.2.5.2 Global Mucin 1 Sales Volume, by Species (2021–2032)
3.2.5.3 Global Mucin 1 Sales Volume, by Species (%), 2021–2032
3.2.6 Global Mucin 1 Average Price by Species (2021–2032)
3.3 Introduction by Physical Form
3.3.1 Lyophilized Powder
3.3.2 Liquid Reagent
3.3.3 Global Mucin 1 Sales Value by Physical Form
3.3.3.1 Global Mucin 1 Sales Value by Physical Form (2021 vs 2025 vs 2032)
3.3.3.2 Global Mucin 1 Sales Value, by Physical Form (2021–2032)
3.3.3.3 Global Mucin 1 Sales Value, by Physical Form (%), 2021–2032
3.3.4 Global Mucin 1 Sales Volume by Physical Form
3.3.4.1 Global Mucin 1 Sales Volume by Physical Form (2021 vs 2025 vs 2032)
3.3.4.2 Global Mucin 1 Sales Volume, by Physical Form (2021–2032)
3.3.4.3 Global Mucin 1 Sales Volume, by Physical Form (%), 2021–2032
3.3.5 Global Mucin 1 Average Price by Physical Form (2021–2032)
3.4 Introduction by Manufacturing Method
3.4.1 Recombinant Expression Product
3.4.2 Synthetic Peptide Product
3.4.3 Antibody Production Product
3.4.4 Global Mucin 1 Sales Value by Manufacturing Method
3.4.4.1 Global Mucin 1 Sales Value by Manufacturing Method (2021 vs 2025 vs 2032)
3.4.4.2 Global Mucin 1 Sales Value, by Manufacturing Method (2021–2032)
3.4.4.3 Global Mucin 1 Sales Value, by Manufacturing Method (%), 2021–2032
3.4.5 Global Mucin 1 Sales Volume by Manufacturing Method
3.4.5.1 Global Mucin 1 Sales Volume by Manufacturing Method (2021 vs 2025 vs 2032)
3.4.5.2 Global Mucin 1 Sales Volume, by Manufacturing Method (2021–2032)
3.4.5.3 Global Mucin 1 Sales Volume, by Manufacturing Method (%), 2021–2032
3.4.6 Global Mucin 1 Average Price by Manufacturing Method (2021–2032)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Prostate Cancer
4.1.2 Breast Cancer
4.1.3 Colon Cancer
4.1.4 Ovarian Cancer
4.1.5 Others
4.2 Global Mucin 1 Sales Value by Application
4.2.1 Global Mucin 1 Sales Value by Application (2021 vs 2025 vs 2032)
4.2.2 Global Mucin 1 Sales Value, by Application (2021–2032)
4.2.3 Global Mucin 1 Sales Value, by Application (%), 2021–2032
4.3 Global Mucin 1 Sales Volume by Application
4.3.1 Global Mucin 1 Sales Volume by Application (2021 vs 2025 vs 2032)
4.3.2 Global Mucin 1 Sales Volume, by Application (2021–2032)
4.3.3 Global Mucin 1 Sales Volume, by Application (%), 2021–2032
4.4 Global Mucin 1 Average Price by Application (2021–2032)
5 Segmentation by Region
5.1 Global Mucin 1 Sales Value by Region
5.1.1 Global Mucin 1 Sales Value by Region: 2021 vs 2025 vs 2032
5.1.2 Global Mucin 1 Sales Value by Region (2021–2026)
5.1.3 Global Mucin 1 Sales Value by Region (2027–2032)
5.1.4 Global Mucin 1 Sales Value by Region (%), 2021–2032
5.2 Global Mucin 1 Sales Volume by Region
5.2.1 Global Mucin 1 Sales Volume by Region: 2021 vs 2025 vs 2032
5.2.2 Global Mucin 1 Sales Volume by Region (2021–2026)
5.2.3 Global Mucin 1 Sales Volume by Region (2027–2032)
5.2.4 Global Mucin 1 Sales Volume by Region (%), 2021–2032
5.3 Global Mucin 1 Average Price by Region (2021–2032)
5.4 North America
5.4.1 North America Mucin 1 Sales Value, 2021–2032
5.4.2 North America Mucin 1 Sales Value by Country (%), 2025 vs 2032
5.5 Europe
5.5.1 Europe Mucin 1 Sales Value, 2021–2032
5.5.2 Europe Mucin 1 Sales Value by Country (%), 2025 vs 2032
5.6 Asia Pacific
5.6.1 Asia Pacific Mucin 1 Sales Value, 2021–2032
5.6.2 Asia Pacific Mucin 1 Sales Value by Region (%), 2025 vs 2032
5.7 South America
5.7.1 South America Mucin 1 Sales Value, 2021–2032
5.7.2 South America Mucin 1 Sales Value by Country (%), 2025 vs 2032
5.8 Middle East & Africa
5.8.1 Middle East & Africa Mucin 1 Sales Value, 2021–2032
5.8.2 Middle East & Africa Mucin 1 Sales Value by Country (%), 2025 vs 2032
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Mucin 1 Sales Value Growth Trends, 2021 vs 2025 vs 2032
6.2 Key Countries/Regions Mucin 1 Sales Value and Sales Volume
6.2.1 Key Countries/Regions Mucin 1 Sales Value, 2021–2032
6.2.2 Key Countries/Regions Mucin 1 Sales Volume, 2021–2032
6.3 United States
6.3.1 United States Mucin 1 Sales Value, 2021–2032
6.3.2 United States Mucin 1 Sales Value by Type (%), 2025 vs 2032
6.3.3 United States Mucin 1 Sales Value by Application, 2025 vs 2032
6.4 Europe
6.4.1 Europe Mucin 1 Sales Value, 2021–2032
6.4.2 Europe Mucin 1 Sales Value by Type (%), 2025 vs 2032
6.4.3 Europe Mucin 1 Sales Value by Application, 2025 vs 2032
6.5 China
6.5.1 China Mucin 1 Sales Value, 2021–2032
6.5.2 China Mucin 1 Sales Value by Type (%), 2025 vs 2032
6.5.3 China Mucin 1 Sales Value by Application, 2025 vs 2032
6.6 Japan
6.6.1 Japan Mucin 1 Sales Value, 2021–2032
6.6.2 Japan Mucin 1 Sales Value by Type (%), 2025 vs 2032
6.6.3 Japan Mucin 1 Sales Value by Application, 2025 vs 2032
6.7 South Korea
6.7.1 South Korea Mucin 1 Sales Value, 2021–2032
6.7.2 South Korea Mucin 1 Sales Value by Type (%), 2025 vs 2032
6.7.3 South Korea Mucin 1 Sales Value by Application, 2025 vs 2032
6.8 Southeast Asia
6.8.1 Southeast Asia Mucin 1 Sales Value, 2021–2032
6.8.2 Southeast Asia Mucin 1 Sales Value by Type (%), 2025 vs 2032
6.8.3 Southeast Asia Mucin 1 Sales Value by Application, 2025 vs 2032
6.9 India
6.9.1 India Mucin 1 Sales Value, 2021–2032
6.9.2 India Mucin 1 Sales Value by Type (%), 2025 vs 2032
6.9.3 India Mucin 1 Sales Value by Application, 2025 vs 2032
7 Company Profiles
7.1 Thermo Fisher Scientific
7.1.1 Thermo Fisher Scientific Company Information
7.1.2 Thermo Fisher Scientific Introduction and Business Overview
7.1.3 Thermo Fisher Scientific Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.1.4 Thermo Fisher Scientific Mucin 1 Product Offerings
7.1.5 Thermo Fisher Scientific Recent Developments
7.2 Roche Diagnostics
7.2.1 Roche Diagnostics Company Information
7.2.2 Roche Diagnostics Introduction and Business Overview
7.2.3 Roche Diagnostics Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.2.4 Roche Diagnostics Mucin 1 Product Offerings
7.2.5 Roche Diagnostics Recent Developments
7.3 Abbott
7.3.1 Abbott Company Information
7.3.2 Abbott Introduction and Business Overview
7.3.3 Abbott Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.3.4 Abbott Mucin 1 Product Offerings
7.3.5 Abbott Recent Developments
7.4 Siemens Healthineers
7.4.1 Siemens Healthineers Company Information
7.4.2 Siemens Healthineers Introduction and Business Overview
7.4.3 Siemens Healthineers Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.4.4 Siemens Healthineers Mucin 1 Product Offerings
7.4.5 Siemens Healthineers Recent Developments
7.5 Beckman Coulter
7.5.1 Beckman Coulter Company Information
7.5.2 Beckman Coulter Introduction and Business Overview
7.5.3 Beckman Coulter Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.5.4 Beckman Coulter Mucin 1 Product Offerings
7.5.5 Beckman Coulter Recent Developments
7.6 DiaSorin
7.6.1 DiaSorin Company Information
7.6.2 DiaSorin Introduction and Business Overview
7.6.3 DiaSorin Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.6.4 DiaSorin Mucin 1 Product Offerings
7.6.5 DiaSorin Recent Developments
7.7 Merck KGaA
7.7.1 Merck KGaA Company Information
7.7.2 Merck KGaA Introduction and Business Overview
7.7.3 Merck KGaA Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.7.4 Merck KGaA Mucin 1 Product Offerings
7.7.5 Merck KGaA Recent Developments
7.8 BD
7.8.1 BD Company Information
7.8.2 BD Introduction and Business Overview
7.8.3 BD Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.8.4 BD Mucin 1 Product Offerings
7.8.5 BD Recent Developments
7.9 Bio-Rad Laboratories
7.9.1 Bio-Rad Laboratories Company Information
7.9.2 Bio-Rad Laboratories Introduction and Business Overview
7.9.3 Bio-Rad Laboratories Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.9.4 Bio-Rad Laboratories Mucin 1 Product Offerings
7.9.5 Bio-Rad Laboratories Recent Developments
7.10 Agilent Technologies
7.10.1 Agilent Technologies Company Information
7.10.2 Agilent Technologies Introduction and Business Overview
7.10.3 Agilent Technologies Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.10.4 Agilent Technologies Mucin 1 Product Offerings
7.10.5 Agilent Technologies Recent Developments
7.11 Leica Biosystems
7.11.1 Leica Biosystems Company Information
7.11.2 Leica Biosystems Introduction and Business Overview
7.11.3 Leica Biosystems Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.11.4 Leica Biosystems Mucin 1 Product Offerings
7.11.5 Leica Biosystems Recent Developments
7.12 Bio-Techne
7.12.1 Bio-Techne Company Information
7.12.2 Bio-Techne Introduction and Business Overview
7.12.3 Bio-Techne Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.12.4 Bio-Techne Mucin 1 Product Offerings
7.12.5 Bio-Techne Recent Developments
7.13 Abcam
7.13.1 Abcam Company Information
7.13.2 Abcam Introduction and Business Overview
7.13.3 Abcam Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.13.4 Abcam Mucin 1 Product Offerings
7.13.5 Abcam Recent Developments
7.14 Cell Signaling Technology
7.14.1 Cell Signaling Technology Company Information
7.14.2 Cell Signaling Technology Introduction and Business Overview
7.14.3 Cell Signaling Technology Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.14.4 Cell Signaling Technology Mucin 1 Product Offerings
7.14.5 Cell Signaling Technology Recent Developments
7.15 BioLegend
7.15.1 BioLegend Company Information
7.15.2 BioLegend Introduction and Business Overview
7.15.3 BioLegend Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.15.4 BioLegend Mucin 1 Product Offerings
7.15.5 BioLegend Recent Developments
7.16 Miltenyi Biotec
7.16.1 Miltenyi Biotec Company Information
7.16.2 Miltenyi Biotec Introduction and Business Overview
7.16.3 Miltenyi Biotec Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.16.4 Miltenyi Biotec Mucin 1 Product Offerings
7.16.5 Miltenyi Biotec Recent Developments
7.17 Fujirebio
7.17.1 Fujirebio Company Information
7.17.2 Fujirebio Introduction and Business Overview
7.17.3 Fujirebio Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.17.4 Fujirebio Mucin 1 Product Offerings
7.17.5 Fujirebio Recent Developments
7.18 Medix Biochemica
7.18.1 Medix Biochemica Company Information
7.18.2 Medix Biochemica Introduction and Business Overview
7.18.3 Medix Biochemica Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.18.4 Medix Biochemica Mucin 1 Product Offerings
7.18.5 Medix Biochemica Recent Developments
7.19 Sino Biological
7.19.1 Sino Biological Company Information
7.19.2 Sino Biological Introduction and Business Overview
7.19.3 Sino Biological Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.19.4 Sino Biological Mucin 1 Product Offerings
7.19.5 Sino Biological Recent Developments
7.20 ACROBiosystems
7.20.1 ACROBiosystems Company Information
7.20.2 ACROBiosystems Introduction and Business Overview
7.20.3 ACROBiosystems Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.20.4 ACROBiosystems Mucin 1 Product Offerings
7.20.5 ACROBiosystems Recent Developments
7.21 Proteintech
7.21.1 Proteintech Company Information
7.21.2 Proteintech Introduction and Business Overview
7.21.3 Proteintech Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.21.4 Proteintech Mucin 1 Product Offerings
7.21.5 Proteintech Recent Developments
7.22 ABclonal
7.22.1 ABclonal Company Information
7.22.2 ABclonal Introduction and Business Overview
7.22.3 ABclonal Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.22.4 ABclonal Mucin 1 Product Offerings
7.22.5 ABclonal Recent Developments
7.23 OriGene
7.23.1 OriGene Company Information
7.23.2 OriGene Introduction and Business Overview
7.23.3 OriGene Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.23.4 OriGene Mucin 1 Product Offerings
7.23.5 OriGene Recent Developments
7.24 Santa Cruz Biotechnology
7.24.1 Santa Cruz Biotechnology Company Information
7.24.2 Santa Cruz Biotechnology Introduction and Business Overview
7.24.3 Santa Cruz Biotechnology Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.24.4 Santa Cruz Biotechnology Mucin 1 Product Offerings
7.24.5 Santa Cruz Biotechnology Recent Developments
7.25 GeneTex
7.25.1 GeneTex Company Information
7.25.2 GeneTex Introduction and Business Overview
7.25.3 GeneTex Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.25.4 GeneTex Mucin 1 Product Offerings
7.25.5 GeneTex Recent Developments
7.26 Atlas Antibodies
7.26.1 Atlas Antibodies Company Information
7.26.2 Atlas Antibodies Introduction and Business Overview
7.26.3 Atlas Antibodies Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.26.4 Atlas Antibodies Mucin 1 Product Offerings
7.26.5 Atlas Antibodies Recent Developments
7.27 Abnova
7.27.1 Abnova Company Information
7.27.2 Abnova Introduction and Business Overview
7.27.3 Abnova Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.27.4 Abnova Mucin 1 Product Offerings
7.27.5 Abnova Recent Developments
7.28 Boster Bio
7.28.1 Boster Bio Company Information
7.28.2 Boster Bio Introduction and Business Overview
7.28.3 Boster Bio Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.28.4 Boster Bio Mucin 1 Product Offerings
7.28.5 Boster Bio Recent Developments
7.29 Elabscience
7.29.1 Elabscience Company Information
7.29.2 Elabscience Introduction and Business Overview
7.29.3 Elabscience Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.29.4 Elabscience Mucin 1 Product Offerings
7.29.5 Elabscience Recent Developments
7.30 CUSABIO
7.30.1 CUSABIO Company Information
7.30.2 CUSABIO Introduction and Business Overview
7.30.3 CUSABIO Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.30.4 CUSABIO Mucin 1 Product Offerings
7.30.5 CUSABIO Recent Developments
7.31 Cloud-Clone
7.31.1 Cloud-Clone Company Information
7.31.2 Cloud-Clone Introduction and Business Overview
7.31.3 Cloud-Clone Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.31.4 Cloud-Clone Mucin 1 Product Offerings
7.31.5 Cloud-Clone Recent Developments
7.32 FineTest
7.32.1 FineTest Company Information
7.32.2 FineTest Introduction and Business Overview
7.32.3 FineTest Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.32.4 FineTest Mucin 1 Product Offerings
7.32.5 FineTest Recent Developments
7.33 RayBiotech
7.33.1 RayBiotech Company Information
7.33.2 RayBiotech Introduction and Business Overview
7.33.3 RayBiotech Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.33.4 RayBiotech Mucin 1 Product Offerings
7.33.5 RayBiotech Recent Developments
7.34 Creative Diagnostics
7.34.1 Creative Diagnostics Company Information
7.34.2 Creative Diagnostics Introduction and Business Overview
7.34.3 Creative Diagnostics Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.34.4 Creative Diagnostics Mucin 1 Product Offerings
7.34.5 Creative Diagnostics Recent Developments
7.35 Creative BioMart
7.35.1 Creative BioMart Company Information
7.35.2 Creative BioMart Introduction and Business Overview
7.35.3 Creative BioMart Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.35.4 Creative BioMart Mucin 1 Product Offerings
7.35.5 Creative BioMart Recent Developments
7.36 Boditech Med
7.36.1 Boditech Med Company Information
7.36.2 Boditech Med Introduction and Business Overview
7.36.3 Boditech Med Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.36.4 Boditech Med Mucin 1 Product Offerings
7.36.5 Boditech Med Recent Developments
7.37 Daiichi Sankyo
7.37.1 Daiichi Sankyo Company Information
7.37.2 Daiichi Sankyo Introduction and Business Overview
7.37.3 Daiichi Sankyo Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.37.4 Daiichi Sankyo Mucin 1 Product Offerings
7.37.5 Daiichi Sankyo Recent Developments
7.38 ImmunityBio
7.38.1 ImmunityBio Company Information
7.38.2 ImmunityBio Introduction and Business Overview
7.38.3 ImmunityBio Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.38.4 ImmunityBio Mucin 1 Product Offerings
7.38.5 ImmunityBio Recent Developments
7.39 GeoVax
7.39.1 GeoVax Company Information
7.39.2 GeoVax Introduction and Business Overview
7.39.3 GeoVax Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.39.4 GeoVax Mucin 1 Product Offerings
7.39.5 GeoVax Recent Developments
7.40 Minerva Biotechnologies
7.40.1 Minerva Biotechnologies Company Information
7.40.2 Minerva Biotechnologies Introduction and Business Overview
7.40.3 Minerva Biotechnologies Mucin 1 Sales, Revenue, Price and Gross Margin (2021–2026)
7.40.4 Minerva Biotechnologies Mucin 1 Product Offerings
7.40.5 Minerva Biotechnologies Recent Developments
8 Industry Chain Analysis
8.1 Mucin 1 Industrial Chain
8.2 Mucin 1 Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Key Suppliers of Raw Materials
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customer Analysis)
8.5 Sales Model and Sales Channelss
8.5.1 Mucin 1 Sales Model
8.5.2 Sales Channels
8.5.3 Mucin 1 Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Mucin 1 Market Trends
Table 2. Mucin 1 Market Drivers & Opportunities
Table 3. Mucin 1 Market Challenges
Table 4. Mucin 1 Market Restraints
Table 5. Global Mucin 1 Revenue by Company (US$ Million), 2021–2026
Table 6. Global Mucin 1 Revenue Market Share by Company (2021–2026)
Table 7. Global Mucin 1 Sales Volume by Company (K Dose), 2021–2026
Table 8. Global Mucin 1 Sales Volume Market Share by Company (2021–2026)
Table 9. Global Market Mucin 1 Price by Company (US$/Dose), 2021–2026
Table 10. Key Manufacturers Mucin 1 Manufacturing Base and Headquarters
Table 11. Key Manufacturers Mucin 1 Product Type
Table 12. Key Manufacturers Start of Mass Production of Mucin 1
Table 13. Global Mucin 1 Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Tier (Tier 1, Tier 2, Tier 3), based on Mucin 1 revenue, 2025
Table 15. Mergers & Acquisitions and Expansion Plans
Table 16. Global Mucin 1 Sales Value by Type: 2021 vs 2025 vs 2032 (US$ Million)
Table 17. Global Mucin 1 Sales Value by Type (US$ Million), 2021–2026
Table 18. Global Mucin 1 Sales Value by Type (US$ Million), 2027–2032
Table 19. Global Mucin 1 Sales Market Share in Value by Type (2021–2026)
Table 20. Global Mucin 1 Sales Market Share in Value by Type (2027–2032)
Table 21. Global Mucin 1 Sales Volume by Type: 2021 vs 2025 vs 2032 (K Dose)
Table 22. Global Mucin 1 Sales Volume by Type (K Dose), 2021–2026
Table 23. Global Mucin 1 Sales Volume by Type (K Dose), 2027–2032
Table 24. Global Mucin 1 Sales Market Share in Volume by Type (2021–2026)
Table 25. Global Mucin 1 Sales Market Share in Volume by Type (2027–2032)
Table 26. Global Mucin 1 Price by Type (US$/Dose), 2021–2026
Table 27. Global Mucin 1 Price by Type (US$/Dose), 2027–2032
Table 28. Global Mucin 1 Sales Value by Species: 2021 vs 2025 vs 2032 (US$ Million)
Table 29. Global Mucin 1 Sales Value by Species (US$ Million), 2021–2026
Table 30. Global Mucin 1 Sales Value by Species (US$ Million), 2027–2032
Table 31. Global Mucin 1 Sales Market Share in Value by Species (2021–2026)
Table 32. Global Mucin 1 Sales Market Share in Value by Species (2027–2032)
Table 33. Global Mucin 1 Sales Volume by Species: 2021 vs 2025 vs 2032 (K Dose)
Table 34. Global Mucin 1 Sales Volume by Species (K Dose), 2021–2026
Table 35. Global Mucin 1 Sales Volume by Species (K Dose), 2027–2032
Table 36. Global Mucin 1 Sales Market Share in Volume by Species (2021–2026)
Table 37. Global Mucin 1 Sales Market Share in Volume by Species (2027–2032)
Table 38. Global Mucin 1 Price by Species (US$/Dose), 2021–2026
Table 39. Global Mucin 1 Price by Species (US$/Dose), 2027–2032
Table 40. Global Mucin 1 Sales Value by Physical Form: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Global Mucin 1 Sales Value by Physical Form (US$ Million), 2021–2026
Table 42. Global Mucin 1 Sales Value by Physical Form (US$ Million), 2027–2032
Table 43. Global Mucin 1 Sales Market Share in Value by Physical Form (2021–2026)
Table 44. Global Mucin 1 Sales Market Share in Value by Physical Form (2027–2032)
Table 45. Global Mucin 1 Sales Volume by Physical Form: 2021 vs 2025 vs 2032 (K Dose)
Table 46. Global Mucin 1 Sales Volume by Physical Form (K Dose), 2021–2026
Table 47. Global Mucin 1 Sales Volume by Physical Form (K Dose), 2027–2032
Table 48. Global Mucin 1 Sales Market Share in Volume by Physical Form (2021–2026)
Table 49. Global Mucin 1 Sales Market Share in Volume by Physical Form (2027–2032)
Table 50. Global Mucin 1 Price by Physical Form (US$/Dose), 2021–2026
Table 51. Global Mucin 1 Price by Physical Form (US$/Dose), 2027–2032
Table 52. Global Mucin 1 Sales Value by Manufacturing Method: 2021 vs 2025 vs 2032 (US$ Million)
Table 53. Global Mucin 1 Sales Value by Manufacturing Method (US$ Million), 2021–2026
Table 54. Global Mucin 1 Sales Value by Manufacturing Method (US$ Million), 2027–2032
Table 55. Global Mucin 1 Sales Market Share in Value by Manufacturing Method (2021–2026)
Table 56. Global Mucin 1 Sales Market Share in Value by Manufacturing Method (2027–2032)
Table 57. Global Mucin 1 Sales Volume by Manufacturing Method: 2021 vs 2025 vs 2032 (K Dose)
Table 58. Global Mucin 1 Sales Volume by Manufacturing Method (K Dose), 2021–2026
Table 59. Global Mucin 1 Sales Volume by Manufacturing Method (K Dose), 2027–2032
Table 60. Global Mucin 1 Sales Market Share in Volume by Manufacturing Method (2021–2026)
Table 61. Global Mucin 1 Sales Market Share in Volume by Manufacturing Method (2027–2032)
Table 62. Global Mucin 1 Price by Manufacturing Method (US$/Dose), 2021–2026
Table 63. Global Mucin 1 Price by Manufacturing Method (US$/Dose), 2027–2032
Table 64. Global Mucin 1 Sales Value by Application: 2021 vs 2025 vs 2032 (US$ Million)
Table 65. Global Mucin 1 Sales Value by Application (US$ Million), 2021–2026
Table 66. Global Mucin 1 Sales Value by Application (US$ Million), 2027–2032
Table 67. Global Mucin 1 Sales Market Share in Value by Application (2021–2026)
Table 68. Global Mucin 1 Sales Market Share in Value by Application (2027–2032)
Table 69. Global Mucin 1 Sales Volume by Application: 2021 vs 2025 vs 2032 (K Dose)
Table 70. Global Mucin 1 Sales Volume by Application (K Dose), 2021–2026
Table 71. Global Mucin 1 Sales Volume by Application (K Dose), 2027–2032
Table 72. Global Mucin 1 Sales Market Share in Volume by Application (2021–2026)
Table 73. Global Mucin 1 Sales Market Share in Volume by Application (2027–2032)
Table 74. Global Mucin 1 Price by Application (US$/Dose), 2021–2026
Table 75. Global Mucin 1 Price by Application (US$/Dose), 2027–2032
Table 76. Global Mucin 1 Sales Value by Region, (US$ Million), 2021 vs 2025 vs 2032
Table 77. Global Mucin 1 Sales Value by Region (US$ Million), 2021–2026
Table 78. Global Mucin 1 Sales Value by Region (US$ Million), 2027–2032
Table 79. Global Mucin 1 Sales Value by Region (%), 2021–2026
Table 80. Global Mucin 1 Sales Value by Region (%), 2027–2032
Table 81. Global Mucin 1 Sales Volume by Region (K Dose): 2021 vs 2025 vs 2032
Table 82. Global Mucin 1 Sales Volume by Region (K Dose), 2021–2026
Table 83. Global Mucin 1 Sales Volume by Region (K Dose), 2027–2032
Table 84. Global Mucin 1 Sales Volume by Region (%), 2021–2026
Table 85. Global Mucin 1 Sales Volume by Region (%), 2027–2032
Table 86. Global Mucin 1 Average Price by Region (US$/Dose), 2021–2026
Table 87. Global Mucin 1 Average Price by Region (US$/Dose), 2027–2032
Table 88. Key Countries/Regions Mucin 1 Sales Value Growth Trends, (US$ Million): 2021 vs 2025 vs 2032
Table 89. Key Countries/Regions Mucin 1 Sales Value, (US$ Million), 2021–2026
Table 90. Key Countries/Regions Mucin 1 Sales Value, (US$ Million), 2027–2032
Table 91. Key Countries/Regions Mucin 1 Sales Volume, (K Dose), 2021–2026
Table 92. Key Countries/Regions Mucin 1 Sales Volume, (K Dose), 2027–2032
Table 93. Thermo Fisher Scientific Company Information
Table 94. Thermo Fisher Scientific Introduction and Business Overview
Table 95. Thermo Fisher Scientific Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 96. Thermo Fisher Scientific Mucin 1 Product Offerings
Table 97. Thermo Fisher Scientific Recent Developments
Table 98. Roche Diagnostics Company Information
Table 99. Roche Diagnostics Introduction and Business Overview
Table 100. Roche Diagnostics Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 101. Roche Diagnostics Mucin 1 Product Offerings
Table 102. Roche Diagnostics Recent Developments
Table 103. Abbott Company Information
Table 104. Abbott Introduction and Business Overview
Table 105. Abbott Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 106. Abbott Mucin 1 Product Offerings
Table 107. Abbott Recent Developments
Table 108. Siemens Healthineers Company Information
Table 109. Siemens Healthineers Introduction and Business Overview
Table 110. Siemens Healthineers Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 111. Siemens Healthineers Mucin 1 Product Offerings
Table 112. Siemens Healthineers Recent Developments
Table 113. Beckman Coulter Company Information
Table 114. Beckman Coulter Introduction and Business Overview
Table 115. Beckman Coulter Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 116. Beckman Coulter Mucin 1 Product Offerings
Table 117. Beckman Coulter Recent Developments
Table 118. DiaSorin Company Information
Table 119. DiaSorin Introduction and Business Overview
Table 120. DiaSorin Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 121. DiaSorin Mucin 1 Product Offerings
Table 122. DiaSorin Recent Developments
Table 123. Merck KGaA Company Information
Table 124. Merck KGaA Introduction and Business Overview
Table 125. Merck KGaA Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 126. Merck KGaA Mucin 1 Product Offerings
Table 127. Merck KGaA Recent Developments
Table 128. BD Company Information
Table 129. BD Introduction and Business Overview
Table 130. BD Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 131. BD Mucin 1 Product Offerings
Table 132. BD Recent Developments
Table 133. Bio-Rad Laboratories Company Information
Table 134. Bio-Rad Laboratories Introduction and Business Overview
Table 135. Bio-Rad Laboratories Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 136. Bio-Rad Laboratories Mucin 1 Product Offerings
Table 137. Bio-Rad Laboratories Recent Developments
Table 138. Agilent Technologies Company Information
Table 139. Agilent Technologies Introduction and Business Overview
Table 140. Agilent Technologies Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 141. Agilent Technologies Mucin 1 Product Offerings
Table 142. Agilent Technologies Recent Developments
Table 143. Leica Biosystems Company Information
Table 144. Leica Biosystems Introduction and Business Overview
Table 145. Leica Biosystems Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 146. Leica Biosystems Mucin 1 Product Offerings
Table 147. Leica Biosystems Recent Developments
Table 148. Bio-Techne Company Information
Table 149. Bio-Techne Introduction and Business Overview
Table 150. Bio-Techne Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 151. Bio-Techne Mucin 1 Product Offerings
Table 152. Bio-Techne Recent Developments
Table 153. Abcam Company Information
Table 154. Abcam Introduction and Business Overview
Table 155. Abcam Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 156. Abcam Mucin 1 Product Offerings
Table 157. Abcam Recent Developments
Table 158. Cell Signaling Technology Company Information
Table 159. Cell Signaling Technology Introduction and Business Overview
Table 160. Cell Signaling Technology Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 161. Cell Signaling Technology Mucin 1 Product Offerings
Table 162. Cell Signaling Technology Recent Developments
Table 163. BioLegend Company Information
Table 164. BioLegend Introduction and Business Overview
Table 165. BioLegend Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 166. BioLegend Mucin 1 Product Offerings
Table 167. BioLegend Recent Developments
Table 168. Miltenyi Biotec Company Information
Table 169. Miltenyi Biotec Introduction and Business Overview
Table 170. Miltenyi Biotec Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 171. Miltenyi Biotec Mucin 1 Product Offerings
Table 172. Miltenyi Biotec Recent Developments
Table 173. Fujirebio Company Information
Table 174. Fujirebio Introduction and Business Overview
Table 175. Fujirebio Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 176. Fujirebio Mucin 1 Product Offerings
Table 177. Fujirebio Recent Developments
Table 178. Medix Biochemica Company Information
Table 179. Medix Biochemica Introduction and Business Overview
Table 180. Medix Biochemica Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 181. Medix Biochemica Mucin 1 Product Offerings
Table 182. Medix Biochemica Recent Developments
Table 183. Sino Biological Company Information
Table 184. Sino Biological Introduction and Business Overview
Table 185. Sino Biological Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 186. Sino Biological Mucin 1 Product Offerings
Table 187. Sino Biological Recent Developments
Table 188. ACROBiosystems Company Information
Table 189. ACROBiosystems Introduction and Business Overview
Table 190. ACROBiosystems Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 191. ACROBiosystems Mucin 1 Product Offerings
Table 192. ACROBiosystems Recent Developments
Table 193. Proteintech Company Information
Table 194. Proteintech Introduction and Business Overview
Table 195. Proteintech Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 196. Proteintech Mucin 1 Product Offerings
Table 197. Proteintech Recent Developments
Table 198. ABclonal Company Information
Table 199. ABclonal Introduction and Business Overview
Table 200. ABclonal Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 201. ABclonal Mucin 1 Product Offerings
Table 202. ABclonal Recent Developments
Table 203. OriGene Company Information
Table 204. OriGene Introduction and Business Overview
Table 205. OriGene Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 206. OriGene Mucin 1 Product Offerings
Table 207. OriGene Recent Developments
Table 208. Santa Cruz Biotechnology Company Information
Table 209. Santa Cruz Biotechnology Introduction and Business Overview
Table 210. Santa Cruz Biotechnology Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 211. Santa Cruz Biotechnology Mucin 1 Product Offerings
Table 212. Santa Cruz Biotechnology Recent Developments
Table 213. GeneTex Company Information
Table 214. GeneTex Introduction and Business Overview
Table 215. GeneTex Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 216. GeneTex Mucin 1 Product Offerings
Table 217. GeneTex Recent Developments
Table 218. Atlas Antibodies Company Information
Table 219. Atlas Antibodies Introduction and Business Overview
Table 220. Atlas Antibodies Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 221. Atlas Antibodies Mucin 1 Product Offerings
Table 222. Atlas Antibodies Recent Developments
Table 223. Abnova Company Information
Table 224. Abnova Introduction and Business Overview
Table 225. Abnova Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 226. Abnova Mucin 1 Product Offerings
Table 227. Abnova Recent Developments
Table 228. Boster Bio Company Information
Table 229. Boster Bio Introduction and Business Overview
Table 230. Boster Bio Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 231. Boster Bio Mucin 1 Product Offerings
Table 232. Boster Bio Recent Developments
Table 233. Elabscience Company Information
Table 234. Elabscience Introduction and Business Overview
Table 235. Elabscience Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 236. Elabscience Mucin 1 Product Offerings
Table 237. Elabscience Recent Developments
Table 238. CUSABIO Company Information
Table 239. CUSABIO Introduction and Business Overview
Table 240. CUSABIO Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 241. CUSABIO Mucin 1 Product Offerings
Table 242. CUSABIO Recent Developments
Table 243. Cloud-Clone Company Information
Table 244. Cloud-Clone Introduction and Business Overview
Table 245. Cloud-Clone Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 246. Cloud-Clone Mucin 1 Product Offerings
Table 247. Cloud-Clone Recent Developments
Table 248. FineTest Company Information
Table 249. FineTest Introduction and Business Overview
Table 250. FineTest Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 251. FineTest Mucin 1 Product Offerings
Table 252. FineTest Recent Developments
Table 253. RayBiotech Company Information
Table 254. RayBiotech Introduction and Business Overview
Table 255. RayBiotech Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 256. RayBiotech Mucin 1 Product Offerings
Table 257. RayBiotech Recent Developments
Table 258. Creative Diagnostics Company Information
Table 259. Creative Diagnostics Introduction and Business Overview
Table 260. Creative Diagnostics Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 261. Creative Diagnostics Mucin 1 Product Offerings
Table 262. Creative Diagnostics Recent Developments
Table 263. Creative BioMart Company Information
Table 264. Creative BioMart Introduction and Business Overview
Table 265. Creative BioMart Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 266. Creative BioMart Mucin 1 Product Offerings
Table 267. Creative BioMart Recent Developments
Table 268. Boditech Med Company Information
Table 269. Boditech Med Introduction and Business Overview
Table 270. Boditech Med Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 271. Boditech Med Mucin 1 Product Offerings
Table 272. Boditech Med Recent Developments
Table 273. Daiichi Sankyo Company Information
Table 274. Daiichi Sankyo Introduction and Business Overview
Table 275. Daiichi Sankyo Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 276. Daiichi Sankyo Mucin 1 Product Offerings
Table 277. Daiichi Sankyo Recent Developments
Table 278. ImmunityBio Company Information
Table 279. ImmunityBio Introduction and Business Overview
Table 280. ImmunityBio Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 281. ImmunityBio Mucin 1 Product Offerings
Table 282. ImmunityBio Recent Developments
Table 283. GeoVax Company Information
Table 284. GeoVax Introduction and Business Overview
Table 285. GeoVax Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 286. GeoVax Mucin 1 Product Offerings
Table 287. GeoVax Recent Developments
Table 288. Minerva Biotechnologies Company Information
Table 289. Minerva Biotechnologies Introduction and Business Overview
Table 290. Minerva Biotechnologies Mucin 1 Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 291. Minerva Biotechnologies Mucin 1 Product Offerings
Table 292. Minerva Biotechnologies Recent Developments
Table 293. Key Raw Materials Lists
Table 294. Key Suppliers of Raw Materials Lists
Table 295. Mucin 1 Downstream Customers
Table 296. Mucin 1 Distributors List
Table 297. Research Programs/Design for This Report
Table 298. Key Data Information from Secondary Sources
Table 299. Key Data Information from Primary Sources
List of Figures
Figure 1. Mucin 1 Product Picture
Figure 2. Global Mucin 1 Sales Value, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Global Mucin 1 Sales Value (US$ Million), 2021–2032
Figure 4. Global Mucin 1 Sales Volume (K Dose), 2021–2032
Figure 5. Global Mucin 1 Sales Price (US$/Dose), 2021–2032
Figure 6. Mucin 1 Report Years Considered
Figure 7. Global Mucin 1 Players Revenue Ranking (US$ Million), 2025
Figure 8. Global Mucin 1 Sales Volume Ranking of Players (K Dose), 2025
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Mucin 1 Revenue in 2025
Figure 10. Mucin 1 Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 11. Mucin 1 Protein Picture
Figure 12. Mucin 1 Peptide Picture
Figure 13. Anti-Mucin 1 Antibody Picture
Figure 14. Global Mucin 1 Sales Value by Type (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global Mucin 1 Sales Value Market Share by Type, 2025 & 2032
Figure 16. Global Mucin 1 Sales Volume by Type (K Dose), 2021 vs 2025 vs 2032
Figure 17. Global Mucin 1 Sales Volume Market Share by Type, 2025 & 2032
Figure 18. Global Mucin 1 Price by Type (US$/Dose), 2021–2032
Figure 19. Human Mucin 1 Picture
Figure 20. Mouse Mucin 1 Picture
Figure 21. Rat Mucin 1 Picture
Figure 22. Global Mucin 1 Sales Value by Species (US$ Million), 2021 vs 2025 vs 2032
Figure 23. Global Mucin 1 Sales Value Market Share by Species, 2025 & 2032
Figure 24. Global Mucin 1 Sales Volume by Species (K Dose), 2021 vs 2025 vs 2032
Figure 25. Global Mucin 1 Sales Volume Market Share by Species, 2025 & 2032
Figure 26. Global Mucin 1 Price by Species (US$/Dose), 2021–2032
Figure 27. Lyophilized Powder Picture
Figure 28. Liquid Reagent Picture
Figure 29. Global Mucin 1 Sales Value by Physical Form (US$ Million), 2021 vs 2025 vs 2032
Figure 30. Global Mucin 1 Sales Value Market Share by Physical Form, 2025 & 2032
Figure 31. Global Mucin 1 Sales Volume by Physical Form (K Dose), 2021 vs 2025 vs 2032
Figure 32. Global Mucin 1 Sales Volume Market Share by Physical Form, 2025 & 2032
Figure 33. Global Mucin 1 Price by Physical Form (US$/Dose), 2021–2032
Figure 34. Recombinant Expression Product Picture
Figure 35. Synthetic Peptide Product Picture
Figure 36. Antibody Production Product Picture
Figure 37. Global Mucin 1 Sales Value by Manufacturing Method (US$ Million), 2021 vs 2025 vs 2032
Figure 38. Global Mucin 1 Sales Value Market Share by Manufacturing Method, 2025 & 2032
Figure 39. Global Mucin 1 Sales Volume by Manufacturing Method (K Dose), 2021 vs 2025 vs 2032
Figure 40. Global Mucin 1 Sales Volume Market Share by Manufacturing Method, 2025 & 2032
Figure 41. Global Mucin 1 Price by Manufacturing Method (US$/Dose), 2021–2032
Figure 42. Product Picture of Prostate Cancer
Figure 43. Product Picture of Breast Cancer
Figure 44. Product Picture of Colon Cancer
Figure 45. Product Picture of Ovarian Cancer
Figure 46. Product Picture of Others
Figure 47. Global Mucin 1 Sales Value by Application (US$ Million), 2021 vs 2025 vs 2032
Figure 48. Global Mucin 1 Sales Value Market Share by Application, 2025 & 2032
Figure 49. Global Mucin 1 Sales Volume by Application (K Dose), 2021 vs 2025 vs 2032
Figure 50. Global Mucin 1 Sales Volume Market Share by Application, 2025 & 2032
Figure 51. Global Mucin 1 Price by Application (US$/Dose), 2021–2032
Figure 52. North America Mucin 1 Sales Value (US$ Million), 2021–2032
Figure 53. North America Mucin 1 Sales Value by Country (%), 2025 vs 2032
Figure 54. Europe Mucin 1 Sales Value (US$ Million), 2021–2032
Figure 55. Europe Mucin 1 Sales Value by Country (%), 2025 vs 2032
Figure 56. Asia Pacific Mucin 1 Sales Value (US$ Million), 2021–2032
Figure 57. Asia Pacific Mucin 1 Sales Value by Region (%), 2025 vs 2032
Figure 58. South America Mucin 1 Sales Value (US$ Million), 2021–2032
Figure 59. South America Mucin 1 Sales Value by Country (%), 2025 vs 2032
Figure 60. Middle East & Africa Mucin 1 Sales Value (US$ Million), 2021–2032
Figure 61. Middle East & Africa Mucin 1 Sales Value by Country (%), 2025 vs 2032
Figure 62. Key Countries/Regions Mucin 1 Sales Value (%), 2021–2032
Figure 63. Key Countries/Regions Mucin 1 Sales Volume (%), 2021–2032
Figure 64. United States Mucin 1 Sales Value (US$ Million), 2021–2032
Figure 65. United States Mucin 1 Sales Value by Type (%), 2025 vs 2032
Figure 66. United States Mucin 1 Sales Value by Application (%), 2025 vs 2032
Figure 67. Europe Mucin 1 Sales Value (US$ Million), 2021–2032
Figure 68. Europe Mucin 1 Sales Value by Type (%), 2025 vs 2032
Figure 69. Europe Mucin 1 Sales Value by Application (%), 2025 vs 2032
Figure 70. China Mucin 1 Sales Value (US$ Million), 2021–2032
Figure 71. China Mucin 1 Sales Value by Type (%), 2025 vs 2032
Figure 72. China Mucin 1 Sales Value by Application (%), 2025 vs 2032
Figure 73. Japan Mucin 1 Sales Value (US$ Million), 2021–2032
Figure 74. Japan Mucin 1 Sales Value by Type (%), 2025 vs 2032
Figure 75. Japan Mucin 1 Sales Value by Application (%), 2025 vs 2032
Figure 76. South Korea Mucin 1 Sales Value (US$ Million), 2021–2032
Figure 77. South Korea Mucin 1 Sales Value by Type (%), 2025 vs 2032
Figure 78. South Korea Mucin 1 Sales Value by Application (%), 2025 vs 2032
Figure 79. Southeast Asia Mucin 1 Sales Value (US$ Million), 2021–2032
Figure 80. Southeast Asia Mucin 1 Sales Value by Type (%), 2025 vs 2032
Figure 81. Southeast Asia Mucin 1 Sales Value by Application (%), 2025 vs 2032
Figure 82. India Mucin 1 Sales Value (US$ Million), 2021–2032
Figure 83. India Mucin 1 Sales Value by Type (%), 2025 vs 2032
Figure 84. India Mucin 1 Sales Value by Application (%), 2025 vs 2032
Figure 85. Mucin 1 Industrial Chain
Figure 86. Mucin 1 Manufacturing Cost Structure
Figure 87. Channels of Distribution (Direct Sales, and Distribution)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which companies rank high in the global Mucin 1 market?
The top companies in the global Mucin 1 market are Thermo Fisher Scientific、Roche Diagnostics、Abbott.
What was the global market size of Mucin 1 in 2032?
Which region is expected to have the highest market share?
What is the annual compound growth rate of the global Mucin 1 market size from 2026 to 2032?
What was the global market size of Mucin 1 in 2026?
Related Reports
Global Mucin 1 Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Mucin 1 market is projected to grow from US$ 300 million in 2025 to US$ 620 million by 2032, at a CAGR of 10.8% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2026-05-30
Pages: 240
USD 4900.00
(Single User License)
Global Mucin 1 Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Mucin 1 market size was US$ 300 million in 2025 and is forecast to reach a readjusted size of US$ 620 million by 2032 with a CAGR of 10.8% during the forecast period 2026-2032.
Published Date: 2026-05-30
Pages: 187
USD 4250.00
(Single User License)
Global Mucin 1 Market Research Report 2026
The global Mucin 1 market was valued at US$ 300 million in 2025 and is anticipated to reach US$ 620 million by 2032, at a CAGR of 10.8% from 2026 to 2032.
Published Date: 2026-05-30
Pages: 175
USD 2900.00
(Single User License)
Global Mucin 1 Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Mucin 1 market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-09-06
Pages: 78
USD 4250.00
(Single User License)
Mucin 1- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Mucin 1 was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-25
Pages: 94
USD 3950.00
(Single User License)
Global Mucin 1 Market Research Report 2025
The global market for Mucin 1 was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-02-25
Pages: 87
USD 2900.00
(Single User License)
Global Mucin 1 Market Insights, Forecast to 2030
The global Mucin 1 market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
Published Date: 2024-04-26
Pages: 87
USD 4900.00
(Single User License)
Global Mucin 1 Market Research Report 2024
The global Mucin 1 market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Published Date: 2024-01-08
Pages: 81
USD 2900.00
(Single User License)
Global Mucin 1 Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Mucin 1 market is projected to grow from US$ 300 million in 2025 to US$ 620 million by 2032, at a CAGR of 10.8% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2026-05-30
Pages: 240
USD 4900.00 (Single User License)Global Mucin 1 Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Mucin 1 market size was US$ 300 million in 2025 and is forecast to reach a readjusted size of US$ 620 million by 2032 with a CAGR of 10.8% during the forecast period 2026-2032.
Published: 2026-05-30
Pages: 187
USD 4250.00 (Single User License)Global Mucin 1 Market Research Report 2026
The global Mucin 1 market was valued at US$ 300 million in 2025 and is anticipated to reach US$ 620 million by 2032, at a CAGR of 10.8% from 2026 to 2032.
Published: 2026-05-30
Pages: 175
USD 2900.00 (Single User License)Global Mucin 1 Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Mucin 1 market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-09-06
Pages: 78
USD 4250.00 (Single User License)Mucin 1- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Mucin 1 was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-25
Pages: 94
USD 3950.00 (Single User License)Global Mucin 1 Market Research Report 2025
The global market for Mucin 1 was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-02-25
Pages: 87
USD 2900.00 (Single User License)Global Mucin 1 Market Insights, Forecast to 2030
The global Mucin 1 market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
Published: 2024-04-26
Pages: 87
USD 4900.00 (Single User License)Global Mucin 1 Market Research Report 2024
The global Mucin 1 market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Published: 2024-01-08
Pages: 81
USD 2900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 3950.00
USD 5925.00
USD 7900.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now